SIG 003
Alternative Names: SIG-003Latest Information Update: 18 Aug 2023
At a glance
- Originator Sigilon Therapeutics
- Class Cell therapies; Gene therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Haemophilia B
Most Recent Events
- 14 Aug 2023 Sigilon Therapeutics has been acquired by Eli Lilly and Company
- 28 Apr 2022 No recent reports of development identified for research development in Haemophilia-B in USA (Implant)
- 23 Sep 2020 SIG 003 is available for licensing as of 23 Sep 2020. https://sigilon.com/